FDA withdraws Covid treatment Evusheld because it's not effective against 93% of subvariants
Evusheld injection, a new COVID-19 treatment that people can take before becoming symptomatic. The Food and Drug Administration on Thursday pulled its authorization for's Evusheld, an antibody injection that people with weak immune systems relied on for additional protection against Covid-19.
The omicron XBB.1.5 subvariant, which is adept at evading antibodies that block infection, has quickly risen in the U.S. and is now causing 49% of new cases, according toEvusheld is also not effective against the BQ.1, BQ.1.1 and XBB subvariants. Taken together with XBB.1.5, versions of Covid that are resistant to Evusheld now represent nearly 93% of new cases in the U.S.
People with compromised immune systems, such as cancer chemotherapy and organ-transplant patients, are some of the groups most vulnerable to severe disease from Covid. withdrew an antibody treatment called bebtelovimabEvusheld is taken as a preventive measure before exposure to Covid. It is a combination of antibodies, cilgavimab and tixagevimab, taken as two injections every six months.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment EvusheldThe U.S. health regulator has withdrawn emergency-use authorization for AstraZeneca's COVID-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.
Consulte Mais informação »
With rise of new coronavirus variants, FDA halts authorization of Evusheld | CNNThe US Food and Drug Administration on Thursday halted the emergency use authorization of Evusheld because it does not appear to protect against Covid-19 from viral variants currently circulating in the United States.
Consulte Mais informação »